

# Ginkgo Adopts Inscripta Platform: Our Take

## TODAY: Syn Bio Panel @ JPM Provides Policy Outlook and Opportunities

- **This morning Ginkgo announced it will utilize Inscripta's Onyx genome engineering technology.** Both company CEO heavyweights will participate in a panel we are hosting this afternoon at the 40<sup>th</sup> Annual JPMorgan Healthcare Conference (virtual). The release is [here](#). Ginkgo notes that the Onyx platform demonstrates an order of magnitude increase in the throughput of certain genome editing capabilities for *S. cerevisiae* and *E. coli*, which led to an increase in strain performance as measured by the production of a target metabolite. The platform delivered faster turnaround times and reduced the design-build-test-learn cycle time by at least 50%, which enables faster product development.
- **Please join us at 5:15 pm EST for a Synthetic Biology Outlook Panel -- with both company CEOs Jason Kelly (Ginkgo) and Sri Kosaraju (Inscripta) - at the JPMorgan Healthcare Conference.** Ipsita Smolinski, Managing Director, Capitol Street and Tycho Peterson Managing Director Life Science Tools & Diagnostics, JP Morgan will co-moderate a diverse panel including:
  - Max Bronstein, Assistant Director, White House Office of Science & Technology Policy
  - Jason Kelly, CEO, Ginkgo Bioworks
  - Sri Kosaraju, President & CEO, Inscripta
  - Gregory Yep, EVP, Chief R&D, Global Integrated and Sustainability Officer, International Flavors & Fragrances
- **White House's Office of Science and Technology Policy (OSTP) research priorities as well as public-private partnerships will be discussed.** Max Bronstein, Assistant Director of Health Innovation at OSTP, will discuss how the synthetic biology and other industries may engage with the government.
- **Our thesis is that the Biden administration will continue investments in advancing life sciences and innovation across industries, including synthetic biology.** The agencies have had a year to hire, prioritize programs; we could see regulatory developments from all agencies, including health initiatives such as HHS, CMS, FDA, NIH, ASPE.
- **2022+ policy catalysts, in our view.**
  - White House Science and Tech Office (OSTP) is led by a geneticist; Dr. Eric Lander is a member of the President's cabinet & leads the path forward.
  - HHS released a RFI (request for information) in 2020 to update Screening Guidance for Synthetic Double Stranded DNA, including whether to incorporate new developments in Synbio. An updated guidance – if released -- could be an opportunity for industry.
  - Biden's ARPA-H Cancer Moonshot was initially envisioned to be \$6.5 B, and the project is likely to be refined in Cures 2.0 legislation in 2022. It's likely a way for innovators, venture capitalists, scientists, foundations & others to work with the government on critical projects.
  - *Endless Frontier* legislation moving forward (passed by the Senate 68-32) is a 2021 bill to out-compete China in key emerging tech areas critical to national security.
- **OUR TAKE:** As noted in the Capitol Street 2022 Health Policy Outlook, we this is a year for the administration to act, in many capacities. We could see new guidances and proposals from the agencies (NIH, FDA, CMS/CMMI, HHS) and White House, we believe Life Sciences and Technology catalysts will flow over the remainder of President Biden's tenure. We anticipate tech

veteran and industry-friendly Rob Califf's Committee vote as FDA Commissioner Wednesday this week (Jan 12), with a full Senate vote as soon as this month, by end of 1Q. Califf is likely to respond to the prolonged pandemic by facilitating regulatory protocol that enables creative public-private partnerships. Synthetic biology and genomic technologies will be tools in the ongoing battle to address current and future outbreaks.